Daniel Forler

Director Business Development – New Platforms, Cardiology & Immunology, Pharmaceuticals Division at Bayer

Speaker

Dr. Daniel Forler is working as a Director for Business Development and Licensing in the department of Business Development & Licensing in the group of Cell & Gene Therapy, Cardiology & Immunology. The function’s mission is to provide access to highly innovative new assets and technology to generate value for patients worldwide.

Daniel studied biology in Freiburg, Leeds and Vancouver and did his PhD in biochemistry at the European Molecular Biology Laboratory (EMBL) in Heidelberg. He completed his PostDoc at Schering AG and started his professional career at Bayer Pharma AG in 2007. He was a laboratory head in target discovery and validation mainly for Oncology. 2013 he changed to Strategic Alliance Management and was responsible for several oncological partnerships and managed Bayer`s biomarker collaborations across all indications. In 2018, he started at Early Licensing and moved for three years to Boston, MA, USA to represent Bayer`s Early Licensing Group in the US. During the last several years, Daniel successfully closed several out- & in-licensing deals with academic and biotech companies. In addition to his BD&L tasks, he is now also involved in the establishment of the Cell & Gene Therapy Translation Center in Berlin.